Funds with similar focus
Fund Name | Location |
415 CAPITAL Management | Bavaria, Germany, Oberhaching |
Accrue Sports and Entertainment Ventures | New York, New York, United States |
Broadfin Capital | New York, New York, United States |
East Africa Capital Partners | Kenya, Nairobi, Nairobi Area |
Ezdehar | - |
Ford Foundation | New York, New York, United States |
Heyihui Capital | Beijing, Beijing, China |
Jundu Investment | Chengguan District, China, Lhasa |
Kiraboshi Bank | Chiyoda, Japan |
Maryland Department of Business and Economic Development | Baltimore, Maryland, United States |
MedCity News | Cleveland, Ohio, United States |
New Oriental Education and Culture Industrial Fund | Beijing, Beijing, China |
Sitka Capital | Barcelona, Catalonia, Spain |
Sonion A/S | Denmark, Roskilde, Sjelland |
Swedbank | Lithuania, Vilniaus Apskritis, Vilnius |
Ubiquiti Networks | - |
Up Group | France, Gennevilliers, Ile-de-France |
Woodline Partners | California, San Francisco, United States |
Zedcrest Capital Limited | Lagos, Lagos, Nigeria |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Insaifeiying | 18 Mar 2024 | Suzhou, Jiangsu, China | |||
Yunmao Technology | 27 Jun 2023 | Xiamen, China | |||
Bioantibody | $15M | 12 Jan 2023 | Nanjing, Jiangsu, China | ||
Keyto | 22 Jan 2021 | Shenzhen, Guangdong, China | |||
MagAssist | $15M | 14 Jan 2021 | Gusu District, Jiangsu, China | ||
Dima Biotech | 11 Sep 2019 | Suzhou, Jiangsu, China | |||
04 Jul 2019 | Gusu District, Jiangsu, China | ||||
Guoke Junhao | $1M | 13 Apr 2019 | Gusu District, Jiangsu, China | ||
EYESEE | $463K | 10 Nov 2017 | Qingyang District, Sichuan, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Insaifeiying | 18 Mar 2024 | Suzhou, Jiangsu, China | |||
Yunmao Technology | 27 Jun 2023 | Xiamen, China | |||
Bioantibody | $15M | 12 Jan 2023 | Nanjing, Jiangsu, China | ||
Keyto | 22 Jan 2021 | Shenzhen, Guangdong, China | |||
MagAssist | $15M | 14 Jan 2021 | Gusu District, Jiangsu, China | ||
Dima Biotech | 11 Sep 2019 | Suzhou, Jiangsu, China | |||
04 Jul 2019 | Gusu District, Jiangsu, China | ||||
Guoke Junhao | $1M | 13 Apr 2019 | Gusu District, Jiangsu, China | ||
EYESEE | $463K | 10 Nov 2017 | Qingyang District, Sichuan, China |